These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 26259981)

  • 1. FGF 19 and Bile Acids Increase Following Roux-en-Y Gastric Bypass but Not After Medical Management in Patients with Type 2 Diabetes.
    Sachdev S; Wang Q; Billington C; Connett J; Ahmed L; Inabnet W; Chua S; Ikramuddin S; Korner J
    Obes Surg; 2016 May; 26(5):957-65. PubMed ID: 26259981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Bile Acids and FGF19 After Sleeve Gastrectomy and Roux-en-Y Gastric Bypass Correlate with Improvement in Type 2 Diabetes in a Randomized Trial.
    Nemati R; Lu J; Dokpuang D; Booth M; Plank LD; Murphy R
    Obes Surg; 2018 Sep; 28(9):2672-2686. PubMed ID: 29987678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute Changes of Bile Acids and FGF19 After Sleeve Gastrectomy and Roux-en-Y Gastric Bypass.
    Chen Y; Lu J; Nemati R; Plank LD; Murphy R
    Obes Surg; 2019 Nov; 29(11):3605-3621. PubMed ID: 31273649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvements in glucose metabolism early after gastric bypass surgery are not explained by increases in total bile acids and fibroblast growth factor 19 concentrations.
    Jørgensen NB; Dirksen C; Bojsen-Møller KN; Kristiansen VB; Wulff BS; Rainteau D; Humbert L; Rehfeld JF; Holst JJ; Madsbad S; Clausen TR
    J Clin Endocrinol Metab; 2015 Mar; 100(3):E396-406. PubMed ID: 25536209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass.
    Gerhard GS; Styer AM; Wood GC; Roesch SL; Petrick AT; Gabrielsen J; Strodel WE; Still CD; Argyropoulos G
    Diabetes Care; 2013 Jul; 36(7):1859-64. PubMed ID: 23801799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preserved Insulin Secretory Capacity and Weight Loss Are the Predominant Predictors of Glycemic Control in Patients With Type 2 Diabetes Randomized to Roux-en-Y Gastric Bypass.
    Nguyen KT; Billington CJ; Vella A; Wang Q; Ahmed L; Bantle JP; Bessler M; Connett JE; Inabnet WB; Thomas A; Ikramuddin S; Korner J
    Diabetes; 2015 Sep; 64(9):3104-10. PubMed ID: 25901097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Manipulating Circulating Bile Acid Concentrations on Postprandial GLP-1 Secretion and Glucose Metabolism After Roux-en-Y Gastric Bypass.
    Jonsson I; Bojsen-Møller KN; Kristiansen VB; Veedfald S; Wewer Albrechtsen NJ; Clausen TR; Kuhre RE; Rehfeld JF; Holst JJ; Madsbad S; Svane MS
    Front Endocrinol (Lausanne); 2021; 12():681116. PubMed ID: 34084153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of Roux-en-Y gastric bypass on postprandial plasma lipid and bile acids kinetics in female non diabetic subjects: A cross-sectional pilot study.
    De Giorgi S; Campos V; Egli L; Toepel U; Carrel G; Cariou B; Rainteau D; Schneiter P; Tappy L; Giusti V
    Clin Nutr; 2015 Oct; 34(5):911-7. PubMed ID: 25306425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids.
    Kohli R; Bradley D; Setchell KD; Eagon JC; Abumrad N; Klein S
    J Clin Endocrinol Metab; 2013 Apr; 98(4):E708-12. PubMed ID: 23457410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roux-en-Y Gastric Bypass Surgery Has Unique Effects on Postprandial FGF21 but Not FGF19 Secretion.
    Harris LLS; Smith GI; Mittendorfer B; Eagon JC; Okunade AL; Patterson BW; Klein S
    J Clin Endocrinol Metab; 2017 Oct; 102(10):3858-3864. PubMed ID: 28938478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity.
    Ahmad NN; Pfalzer A; Kaplan LM
    Int J Obes (Lond); 2013 Dec; 37(12):1553-9. PubMed ID: 23567924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated fasting and postprandial C-terminal telopeptide after Roux-en-Y gastric bypass.
    Maghsoodi N; Alaghband-Zadeh J; Cross GF; Werling M; Fändriks L; Docherty NG; Olbers T; Dew T; Sherwood RA; Vincent RP; le Roux CW
    Ann Clin Biochem; 2017 Jul; 54(4):495-500. PubMed ID: 27555664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery.
    Jansen PL; van Werven J; Aarts E; Berends F; Janssen I; Stoker J; Schaap FG
    Dig Dis; 2011; 29(1):48-51. PubMed ID: 21691104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of Action of Surgical Interventions on Weight-Related Diseases: the Potential Role of Bile Acids.
    Mazidi M; de Caravatto PP; Speakman JR; Cohen RV
    Obes Surg; 2017 Mar; 27(3):826-836. PubMed ID: 28091894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery.
    Werling M; Vincent RP; Cross GF; Marschall HU; Fändriks L; Lönroth H; Taylor DR; Alaghband-Zadeh J; Olbers T; Le Roux CW
    Scand J Gastroenterol; 2013 Nov; 48(11):1257-64. PubMed ID: 24044585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calorie restriction and Roux-en-Y gastric bypass have opposing effects on circulating FGF21 in morbidly obese subjects.
    Lips MA; de Groot GH; Berends FJ; Wiezer R; van Wagensveld BA; Swank DJ; Luijten A; van Dijk KW; Pijl H; Jansen PL; Schaap FG
    Clin Endocrinol (Oxf); 2014 Dec; 81(6):862-70. PubMed ID: 24841294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Increases in Bile Acids Post Roux-en-Y Gastric Bypass Are Driven by Insulin-Sensitizing, Secondary Bile Acids.
    Albaugh VL; Flynn CR; Cai S; Xiao Y; Tamboli RA; Abumrad NN
    J Clin Endocrinol Metab; 2015 Sep; 100(9):E1225-33. PubMed ID: 26196952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolomics Study of Roux-en-Y Gastric Bypass Surgery (RYGB) to Treat Type 2 Diabetes Patients Based on Ultraperformance Liquid Chromatography-Mass Spectrometry.
    Luo P; Yu H; Zhao X; Bao Y; Hong CS; Zhang P; Tu Y; Yin P; Gao P; Wei L; Zhuang Z; Jia W; Xu G
    J Proteome Res; 2016 Apr; 15(4):1288-99. PubMed ID: 26889720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of Bile Acid Profiles, GLP-1, and FGF19 After Laparoscopic Gastric Banding.
    Thöni V; Pfister A; Melmer A; Enrich B; Salzmann K; Kaser S; Lamina C; Ebenbichler CF; Hackl H; Tilg H; Moschen AR
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2974-2984. PubMed ID: 28591793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Sleeve Gastrectomy and Gastric Bypass on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients: a 2-Year Follow-up.
    Griffo E; Cotugno M; Nosso G; Saldalamacchia G; Mangione A; Angrisani L; Rivellese AA; Capaldo B
    Obes Surg; 2016 Jun; 26(6):1247-53. PubMed ID: 26435537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.